Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.52 |
| ▸ | CDK2 | P24941 | 2/20 | 0.52 |
| ▸ | GSK3B | P49841 | 11/20 | 0.48 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | CCND3 | P30281 | 3/20 | 0.45 |
| ▸ | PIM1 | P11309 | 2/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL91480 | 0.89 | CDK4 (0.49) | CDK4CDK2GSK3BRAPGEF4BRAF | |
| SCHEMBL13524613 | 0.83 | GSK3B (0.55) | CDK4CDK2GSK3BRAPGEF4BRAF | |
| SCHEMBL15181324 | 0.82 | SCN9A (0.44) | CDK4CDK2GSK3BGRM4 | |
| SCHEMBL84402 | 0.79 | KCNH2 (0.54) | CDK4CDK2GSK3BDHODH | |
| SCHEMBL84379 | 0.77 | AURKA (0.67) | — | |
| SCHEMBL2956376 | 0.74 | PLK1 (0.68) | CDK4CDK2GSK3BBRAFMAPK14 | |
| SCHEMBL4383661 | 0.74 | CDK2 (0.53) | CDK4CDK2GSK3BBRAFMAPK14 | |
| SCHEMBL6158114 | 0.74 | CDK2 (0.62) | CDK4CDK2CCNA2CCNA1 | |
| SCHEMBL2955040 | 0.73 | GSK3B (0.68) | CDK4CDK2GSK3BBRAFMAPK14 | |
| SCHEMBL5200728 | 0.73 | GSK3B (0.55) | CDK4CDK2GSK3BRAPGEF4BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | CDK4 12/4885CDK2 20/4885GSK3B 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.